TROG Cancer Research
Members Login   CQMS Login  

Lung trials now recruiting

TROG 16.01 (NIVORAD) - A randomised phase II trial of nivolumab and stereotactic ablative body radiotherapy in advanced non-small cell lung cancer, progressing after first or second line chemotherapy.

Primary sponsor: The University of Sydney
Collaborating Groups: ALTG and TROG


TROG 13.01 (SAFRON II) - the aim of this study is to see if stereotactic body radiotherapy has an ‘acceptable’ level of side effects, and will also examine quality of life, cost effectiveness and resource use.

Primary sponsor: TROG
Collaborating group: Australasian Lung Cancer Trials Group
(ALTG)


TROG 11.03 (P_LUNG) - this study investigates whether adding chemotherapy to a short course of radiotherapy results in a greater improvement in symptoms and overall wellbeing compared with using a short course of radiotherapy alone in patients with Non-Small Cell Lung Cancer (NSCLC).

Primary sponsor: TROG

 

We are thankful to our 14,000 patients who have participated in our research. Please continue the generous support.